ARCT
Arcturus Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.58 / 10
Netural
Fund flow metrics are encouraging with a 7.95/10 score, indicating net inflows across block, small, medium, large, and extra-large categories (all trends positive). This positive capital movement contrasts with the weak technicals and neutral analyst sentiment. Only one analyst (Citigroup) provides a Neutral rating, and historical prediction accuracy is low (25%, average return -5.46%). The mismatch between improving fund flows and deteriorating technicals creates an ambiguous near-term picture.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-06
InstitutionCitigroup
Times predicted4
Historical Win Rate25.0%
What is the market sentiment for ARCT?
- ARCT holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.58/10 (Netural).
